重组Anti-HLA-DR抗体[TAL 1B5] (ab20181)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [TAL 1B5] to HLA-DR
- Suitable for: ICC/IF, WB, IHC-P, Flow Cyt
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-HLA-DR抗体[TAL 1B5]
参阅全部 HLA-DR 一抗 -
描述
小鼠单克隆抗体[TAL 1B5] to HLA-DR -
宿主
Mouse -
经测试应用
适用于: ICC/IF, WB, IHC-P, Flow Cytmore details -
种属反应性
与反应: Human -
免疫原
Full length native protein (purified). This information is proprietary to Abcam and/or its suppliers.
-
阳性对照
- WB: Raji and Daudi whole cell lysates; Human colon lysate. IHC-P: Human skin and tonsil tissue sections. Flow Cyt: Human peripheral blood mononuclear cells (PBMCs). ICC/IF: Raji cells.
-
常规说明
This product has switched from a hybridoma to recombinant production method on 23 September 2022.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
TAL 1B5 -
骨髓瘤
P3-NS1/1-Ag4-1 -
同种型
IgG1 -
轻链类型
kappa -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab20181于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
ICC/IF |
1/1000.
|
|
WB | (1) |
Use a concentration of 1 µg/ml. Detects a band of approximately 35 kDa (predicted molecular weight: 29 kDa).
|
IHC-P | (3) |
Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
Flow Cyt |
Use a concentration of 0.008 µg/ml.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
说明 |
---|
ICC/IF
1/1000. |
WB
Use a concentration of 1 µg/ml. Detects a band of approximately 35 kDa (predicted molecular weight: 29 kDa). |
IHC-P
Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Flow Cyt
Use a concentration of 0.008 µg/ml. ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
靶标
-
功能
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. -
序列相似性
Belongs to the MHC class II family.
Contains 1 Ig-like C1-type (immunoglobulin-like) domain. -
翻译后修饰
Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective. -
细胞定位
Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation. - Information by UniProt
-
数据库链接
- Entrez Gene: 3122 Human
- Omim: 142860 Human
- SwissProt: P01903 Human
- Unigene: 520048 Human
-
别名
- DASS-397D15.1 antibody
- DR alpha chain antibody
- DR alpha chain precursor antibody
see all
图片
-
ab20181 staining HLA DR in Raji cells. The cells were fixed with 4% formaldehyde (10 min), permeabilised in 0.1% Triton X-100 for 5 minutes and then blocked in 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab20181 at 1/1000 dilution and ab7291, Mouse monoclonal to alpha Tubulin at 1/1000 dilution. Cells were then incubated with ab150119, Goat Anti-Mouse IgG H&L (Alexa Fluor® 647) preadsorbed, at 1/1000 dilution (shown in red) and ab150081, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488), preadsorbed at 1/1000 dilution (shown in green). Nuclear DNA was labelled with DAPI (shown in blue).
Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8). -
All lanes : Anti-HLA-DR antibody [TAL 1B5] (ab20181) at 1/1000 dilution
Lane 1 : Raji whole cell lysate
Lane 2 : Daudi whole cell lysate
Lane 3 : HEK-293 whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 29 kDa
Observed band size: 35 kDa why is the actual band size different from the predicted?Lanes 1-3: Merged signal (red and green). Green - ab20181 observed at 35 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.
ab20181 was shown to react with HLA-DR in Western blot. Membranes were blocked with 3% milk in TBS-T (0.1% Tween®) before incubation with ab20181 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4°C at 1 µg/ml and a 1:20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1:20000 dilution for 1 h at room temperature before imaging.
-
Immunohistochemical analysis of paraffin-embedded human skin tissue labeling HLA-DR with ab20181 at 0.1 µg/ml followed by Leica DS9800 (Bond™ Polymer Refine Detection). The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab20181, 0.1ug/ml, for 15 mins at room temperature and was then detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling HLA-DR with ab20181 at 0.1 µg/ml followed by Leica DS9800 (Bond™ Polymer Refine Detection). The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab20181, 0.1ug/ml, for 15 mins at room temperature and was then detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
-
Flow cytometry staining of human peripheral blood mononuclear cells (PBMCs) with ab20181 (right) or mouse IgG1κ (ab170190) isotype (left). PBMCs were incubated for 30 min on ice in 1x PBS containing 10μg/ml human IgG and 10% normal goat serum to block FC receptors and non-specific protein-protein interaction followed by followed by staining with CD19 APC. PBMCs were then fixed in 4.2% formaldehyde and permeabilised in 0.1% saponin before staining with the antibody (ab20181) or mouse IgG1κ (ab170190) isotype (1x106 in 100μl; at 0.008μg/ml) for 30 min on ice. The secondary antibody Goat anti-mouse IgG H&L (Alexa Fluor ® 488, pre-adsorbed) (ab150117) was used at 1:2000 dilution for 30 min on ice. Acquisition of >30000 events were collected using a 50 mW Blue laser (488nm) and 525/40 bandpass filter. Events were gated on alive lymphocytes.
-
Anti-HLA-DR antibody [TAL 1B5] (ab20181) at 0.667 µg/ml + whole tissue lysate prepared from human colon at 50 µg
Secondary
HRP conjugated goat anti-mouse polyclonal at 1/3000 dilution
Developed using the ECL technique.
Predicted band size: 29 kDa
Observed band size: 33 kDa why is the actual band size different from the predicted?
Exposure time: 5 secondsThis image was generated from a previous batch made using the hybridoma production method.
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (51)
ab20181 被引用在 51 文献中.
- Fischer JR et al. Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. Cell Rep Med 4:100977 (2023). PubMed: 36921599
- Chaudhary R et al. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. Cancer Res Commun 3:896-907 (2023). PubMed: 37377902
- Phulphagar KM et al. Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry. Mol Cell Proteomics 22:100563 (2023). PubMed: 37142057
- Griesinger AM et al. Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma. iScience 26:107585 (2023). PubMed: 37694144
- Naghavian R et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 617:807-817 (2023). PubMed: 37198490